A. Antón

3.0k total citations · 1 hit paper
103 papers, 1.7k citations indexed

About

A. Antón is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Antón has authored 103 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 40 papers in Cancer Research. Recurrent topics in A. Antón's work include Cancer Treatment and Pharmacology (31 papers), Prostate Cancer Treatment and Research (24 papers) and Breast Cancer Treatment Studies (23 papers). A. Antón is often cited by papers focused on Cancer Treatment and Pharmacology (31 papers), Prostate Cancer Treatment and Research (24 papers) and Breast Cancer Treatment Studies (23 papers). A. Antón collaborates with scholars based in Spain, Australia and United States. A. Antón's co-authors include Catherine M. Kelly, Aňa Lluch, Miguel Ángel Seguí, Rachel Wuerstlein, Filippo Montemurro, Peter Ellis, Suzette Delaloge, Vicente Guillém, Carlos H. Barrios and Étienne Brain and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

A. Antón

100 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Antón Spain	18	1.3k	695	492	256	179	103	1.7k
Federica Cuppone Italy	20	1.1k 0.9×	604 0.9×	388 0.8×	111 0.4×	115 0.6×	50	1.5k
R. Largillier France	14	940 0.7×	334 0.5×	527 1.1×	201 0.8×	198 1.1×	47	1.5k
Pınar Saip Türkiye	21	606 0.5×	520 0.7×	354 0.7×	337 1.3×	76 0.4×	115	1.6k
Catharina Wenzel Austria	22	979 0.8×	376 0.5×	403 0.8×	126 0.5×	216 1.2×	48	1.4k
Vicente Guillém Spain	18	1.2k 1.0×	642 0.9×	394 0.8×	597 2.3×	113 0.6×	52	2.0k
Pavlos Papakostas Greece	26	1.5k 1.2×	841 1.2×	315 0.6×	448 1.8×	182 1.0×	104	2.2k
Lorenzo Gianni Italy	21	1.2k 0.9×	526 0.8×	600 1.2×	150 0.6×	298 1.7×	91	2.0k
Christian Borel France	23	1.2k 0.9×	496 0.7×	494 1.0×	433 1.7×	119 0.7×	78	1.9k
Erich Solomayer Germany	21	1.5k 1.1×	454 0.7×	1.0k 2.0×	235 0.9×	153 0.9×	73	2.3k
Catherine Kennedy Australia	23	785 0.6×	1.1k 1.6×	370 0.8×	227 0.9×	228 1.3×	38	2.0k

Countries citing papers authored by A. Antón

Since Specialization

Citations

This map shows the geographic impact of A. Antón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Antón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Antón more than expected).

Fields of papers citing papers by A. Antón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Antón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Antón. The network helps show where A. Antón may publish in the future.

Co-authorship network of co-authors of A. Antón

This figure shows the co-authorship network connecting the top 25 collaborators of A. Antón. A scholar is included among the top collaborators of A. Antón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Antón. A. Antón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Williams, Colin C., Wei Hong, A. Antón, et al.. (2025). Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 23(3). 102345–102345. 1 indexed citations

Antón, A., et al.. (2024). The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database. Frontiers in Oncology. 14. 1494073–1494073.

Antón, A., Natalie WH Tan, Phillip Parente, et al.. (2024). Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors. JCO Oncology Practice. 20(9). 1231–1242. 1 indexed citations

Antón, A., Ryan Hutchinson, Christopher M. Hovens, et al.. (2024). An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape. PLoS ONE. 19(11). e0301943–e0301943. 3 indexed citations

Lok, Sheau Wen, Richard de Boer, Laeeq Malik, et al.. (2023). Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Research and Treatment. 198(1). 67–74. 7 indexed citations

Lok, Sheau Wen, A. Antón, Sally Baron‐Hay, et al.. (2023). Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.. Journal of Clinical Oncology. 41(16_suppl). e13054–e13054. 1 indexed citations

Trigo, José, Khalil Zaman, María Ángeles Sala, et al.. (2023). EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients. Journal of Thoracic Oncology. 18(11). S708–S709.

Gianni, Luca, Chiun‐Sheng Huang, Daniel Egle, et al.. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Annals of Oncology. 33(5). 534–543. 204 indexed citations breakdown →

Guo, Christina, Allan Ben Smith, Benjamin Thomas, et al.. (2022). Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study. JMIR Cancer. 8(4). e39725–e39725. 2 indexed citations

10.

Antón, A., Shirley Wong, Andrew Weickhardt, et al.. (2021). Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. European Journal of Cancer. 157. 485–492. 8 indexed citations

11.

Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458. 3 indexed citations

12.

Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2021). 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S626–S627. 14 indexed citations

13.

Bianchini, Giampaolo, Matteo Dugo, Chiun‐Sheng Huang, et al.. (2021). LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Annals of Oncology. 32. S1283–S1284. 15 indexed citations

14.

Antón, A., Patrick Bowden, Anthony J. Costello, et al.. (2020). Use of prostate‐specific membrane antigen positron‐emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. British Journal of Urology. 126(4). 433–435. 12 indexed citations

15.

Jensen, Allan, Jeremy Shapiro, Andrew Weickhardt, et al.. (2020). 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1329–S1330. 1 indexed citations

16.

Kwan, Edmond M., Alice R.T. Bergin, A. Antón, et al.. (2019). Impact of access to novel therapies on the initial management of castrate‐resistant prostate cancer: an Australian multicentre study. Internal Medicine Journal. 49(11). 1378–1385. 4 indexed citations

17.

Sánchez‐Rovira, Pedro, Miguel Ángel Seguí, Antonio Llombart‐Cussac, et al.. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology. 15(10). 810–817. 9 indexed citations

18.

Antón, A., A. Ruíz, Arrate Plazaola, et al.. (2010). Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology. 22(1). 74–79. 27 indexed citations

19.

Tabernero, Josep, José A. Martínez-Climent, Aňa Lluch, et al.. (2004). A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals of Oncology. 15(9). 1358–1365. 131 indexed citations

20.

Blanco, Esperanza J. Carcache de, Alfredo Carrato, Joan Maurel, et al.. (1998). Seventy-Two Hour Epirubicin Infusion Plus Quinidine in Unresectable and Metastatic Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology. 21(2). 151–154. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact